A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

• Status: Completed
• Trial end date: 2020-05-14
• Target enrollment: 0
• Participant gender: Female

Summary

The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Midazolam

Criteria

Inclusion Criteria:

• Participant must have hormone receptor positive and HER2 negative metastatic breast cancer

• Participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor

• Participant must be able and willing to undergo mandatory tumor biopsy

• Participant must have normal organ function

• Participant must be able to swallow capsules

Exclusion Criteria:

• Participant must not have had prior chemotherapy for mBC. Chemotherapy in the adjuvant/neoadjuvant setting is permitted

• Participant must not be currently enrolled in a clinical study

• Participant must not have another serious medical condition

• Participant must not have previously received an aurora kinase inhibitor